Latest Research And Development News

EBR Systems has signed a long-term lease for a 51,000 sq ft facility in Santa Clara, California, positioning itself for significant manufacturing expansion and future growth in wireless cardiac pacing technology.

Butn Limited reported a modest net cash increase from operating activities in the December 2024 quarter, ending with a strong cash balance of $16.8 million. The fintech company’s latest cash flow report reveals ongoing investment and notable payments to related parties.

Phoslock Environmental Technologies reported a widening cashflow deficit and disappointing sales in the December 2024 quarter, while legal challenges and share suspension continue to cloud its outlook.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Amcor plc has taken a pivotal step in its proposed merger with Berry Global by filing the definitive joint proxy statement with the SEC, setting the stage for shareholder votes in February. Integration planning is well underway as both companies prepare to unite their packaging expertise.

Adisyn Ltd has successfully raised $10 million through a heavily oversubscribed placement, signaling strong institutional confidence in its graphene-enhanced semiconductor technology. The capital will accelerate development, commercial partnerships, and operational scaling.

Galilee Energy reports a $1.9 million R&D tax refund and terminates its merger with Vintage Energy, while maintaining steady progress at its Glenaras Gas Project and a robust cash position of $4.38 million.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Australian Silica Quartz Group reports promising gold intersections at Koolyanobbing Metals Project and progresses its Quartz Hill silica project with positive metallurgical results and strategic funding.

VHM Limited has secured ministerial endorsement for its Goschen Project Environmental Effects Statement, paving the way for a Final Investment Decision and targeted production in 2026. The company also advanced financing and strategic appointments to support its development trajectory.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.